AWS Launches Amazon Bio Discovery, an AI Agent Platform That Connects Drug Design to Physical Lab Testing

AWS announced Amazon Bio Discovery on April 15, an AI-powered application that connects computational drug design to physical laboratory testing through an integrated AI agent. The platform ships with more than 40 biological foundation models (bioFMs), an AI agent that guides scientists through experiment design, and a network of contract research partners including Twist Bioscience, Ginkgo Bioworks, and A-Alpha Bio for physical synthesis and testing, according to About Amazon.

The core architecture is what AWS calls “lab-in-the-loop”: the AI agent doesn’t just analyze data and return recommendations. It routes the most promising drug candidates to physical labs for synthesis, receives test results back into the application, and uses those results to refine the next round of computational design. This creates a feedback cycle between AI prediction and wet-lab validation.

How It Works

Amazon Bio Discovery operates through a four-stage process, according to Pharmaphorum:

First, scientists evaluate models from the 40+ bioFM catalog and build computational workflows. Second, the AI agent guides experimental design using natural language, allowing scientists to describe their research goals in domain-specific terminology rather than writing code. Third, the agent analyzes computational results and identifies the most promising candidates. Fourth, those candidates transfer directly to integrated lab partners for physical synthesis and testing, with results feeding back into the system.

“AI agents make powerful scientific capabilities accessible to all drug researchers, not just those with computational expertise,” said Rajiv Chopra, vice president of AWS Healthcare AI and Life Sciences, in the announcement. “These AI systems can help scientists design drug molecules, coordinate testing, learn from results, and get smarter with each experiment.”

Scientists can also fine-tune models with their own proprietary experimental data to improve predictions across successive iterations, and deploy custom in-house models within the platform. All fine-tuned models remain private to the user or their organization, according to AWS.

Memorial Sloan Kettering Validation

Memorial Sloan Kettering Cancer Center used the platform to generate 100,000 antibody candidates for pediatric cancer testing in weeks rather than months, according to Pharmaphorum, which cited a published white paper describing the work. The AWS product page reports the platform was used to design nearly 300,000 novel antibody molecules total, with the top 100,000 sent for testing.

AWS vice president Chopra told Reuters that Amazon Bio Discovery is already being used at Bayer, the Broad Institute, and Voyager Therapeutics.

The Competitive Landscape

The launch puts AWS in direct competition with NVIDIA, Alphabet’s Isomorphic Labs, and OpenAI in the AI drug discovery space, as Pharmaphorum noted. AWS’s existing enterprise position (19 of the top 20 pharma multinationals already use AWS for research workloads) gives it a distribution advantage that pure-play drug discovery AI companies lack.

Amazon Bio Discovery’s launch on April 15 landed within 24 hours of Novo Nordisk’s enterprise-wide OpenAI partnership announcement. Two different deployment models for the same bet: AWS built a dedicated agentic platform for drug discovery; OpenAI signed an enterprise integration deal covering all of Novo Nordisk’s operations. For scientists and builders working at the intersection of AI and life sciences, both architectures are now available and backed by hyperscaler-level infrastructure.